| Trials | Arm | Events % (No. of events/No. entered) | |||||||
| Nausea | Fatigue | Vomiting | Anaemia | Diarrhoea | Constipation | Abdominal pain | Dyspepsia | ||
| Andrew Tutt [14] | 400 mg bid | 56% (15/27) | 56% (15/27) | 22% (6/27) | 15% (4/27) | 11% (3/27) | 7% (2/27) | 7% (2/27) | 7% (2/27) |
| 100 mg bid | 41% (11/27) | 30% (8/27) | 15% (4/27) | 15% (4/27) | 7% (2/27) | 15% (4/27) | 11% (3/27) | 4% (1/27) | |
| M. William Audeh [13] | 400 mg bid | 48% (16/33) | 33% (11/33) | 12% (4/33) | 18% (6/33) | 15% (5/33) | 3% (1/33) | 9% (3/33) | 6% (2/33) |
| 100 mg bid | 37% (9/24) | 37% (9/24) | 0% (0/24) | 17% (4/24) | 12% (3/24) | 8% (2/24) | 0% (0/24) | 12% (3/24) | |
| Karen A. Gelmon [18] | Ovarian cancer 400 mg bid | 66% (42/64) | 70% (45/64) | 39% (25/64) | NA | 23% (15/64) | NA | 20% (13/64) | 23% (15/64) |
| Stan B. Kaye [19] | 200 mg bid | 59% (19/32) | 41% (13/32) | 34% (11/32) | 12% (4/32) | 19% (6/32) | 28% (9/32) | 37% (12/32) | NA |
| 400 mg bid | 78% (25/32) | 66% (21/32) | 50% (16/32) | 31% (10/32) | 37% (12/32) | 16% (5/32) | 25% (8/32) | NA | |
| PLD 50 mg/m2 | 54% (18/33) | 45% (15/33) | 30% (10/33) | 3% (1/33) | 30% (10/33) | 36% (12/33) | 36% (12/33) | NA | |
| Jonathan Ledermann [12] [23] | 400 mg bid | 71% (96/136) | 52% (71/136) | 34% (46/136) | 21% (29/136) | 27% (37/136) | 21% (28/136) | 25% (34/136) | 18% (24/136) |
| Placebo | 36% (46/129) | 39% (50/129) | 14% (18/129) | 5% (7/129) | 24% (31/129) | 11% (14/129) | 26% (34/129) | 8% (11/129) | |
| Bella Kaufman [20] | Breast cancer 400 mg bid | 53% (33/62) | 48% (30/62) | 34% (21/62) | 26% (16/62) | 18% (11/62) | NA | 8% (5/62) | 14% (9/62) |
| Ovarian cancer 400 mg bid | 62% (119/193) | 60% (116/193) | 39% (75/193) | 32% (62/193) | 29% (56/193) | NA | 30% (58/193) | 20% (38/193) | |